ALEC:NSD-Alector, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 16.12

Change

-0.23 (-1.41)%

Market Cap

USD 1.30B

Volume

0.47M

Average Target Price

USD 33.00 (+104.71%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.

Company Website : http://www.alector.com

Address : 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Employees : 181

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.02

52 Week High : 34.89

Short Ratio : 7.59

52 Week Low : 9.12

Shorted Shares : 6,142,320

200 Day Moving Average : 16.18

Shorted Shares Previous Month : 5,808,385

50 Day Moving Average : 18.41

Shares Held By Insiders : 127.27%

Short Percentage : 8.00%

Shares Held by Institutions : 75.75%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.60 (-2.82%)

 USD65.51B 109.35 N/A
VRTX Vertex Pharmaceuticals Incorpo..

-2.11 (-0.98%)

 USD55.66B 20.49 14.38
REGN Regeneron Pharmaceuticals, Inc

+5.59 (+1.13%)

 USD52.92B 16.28 12.68
BNTX BioNTech SE

+18.64 (+10.15%)

 USD44.37B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.38 (+0.81%)

 USD37.67B 55.32 39.57
BGNE BeiGene, Ltd

-8.65 (-2.77%)

 USD28.69B N/A N/A
SGEN Seagen Inc

-3.56 (-2.55%)

 USD25.31B 38.92 34.59
RPRX Royalty Pharma plc

+0.52 (+1.27%)

 USD24.87B 22.60 14.92
GMAB Genmab A/S

-0.16 (-0.43%)

 USD24.33B 26.59 3.07
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ALEC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.54% 67% D+ 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.54% 67% D+ 52% F
Trailing 12 Months  
Capital Gain -44.59% 17% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.59% 17% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.09% 31% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.09% 31% F 22% F
Risk Return Profile  
Volatility (Standard Deviation) 26.97% 90% A- 63% D
Risk Adjusted Return -4.05% 30% F 22% F
Market Capitalization 1.30B 77% C+ 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.87 45% F 34% F
Price / Cash Flow Ratio -7.82 50% F 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -65.33% 46% F 18% F
Return on Invested Capital -84.44% 24% F 9% F
Return on Assets -24.25% 53% F 16% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.59 25% F 12% F
Short Percent 10.81% 31% F 19% F
Beta 1.02 70% C- 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.